Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 81, 2021 - Issue 4
Submit an article Journal homepage
1,972
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Soluble ST2, a biomarker of fibrosis, is associated with multiple risk factors, chronic diseases and total mortality in the OPERA study

Yasmina FilaliMedical Research Centre Oulu, Unit of Internal Medicine, Oulu University Hospital, University of Oulu, Oulu, Finland
,
Y. Antero KesäniemiMedical Research Centre Oulu, Unit of Internal Medicine, Oulu University Hospital, University of Oulu, Oulu, Finland
&
Olavi UkkolaMedical Research Centre Oulu, Unit of Internal Medicine, Oulu University Hospital, University of Oulu, Oulu, FinlandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7414-2608
ORCID Icon
Pages 324-331 | Received 07 Jan 2021, Accepted 14 Mar 2021, Published online: 01 Apr 2021

References

  • Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028–1040.
  • Dattagupta A, Immaneni S. ST2: current status. Indian Heart J. 2018;70:S96–S101.
  • Pascual-Figal DA, Januzzi JL. The biology of ST2: the international ST2 consensus panel. Am J Cardiol. 2015;115(7 Suppl.):3B–7B.
  • Aimo A, Migliorini P, Vergaro G, et al. The IL-33/ST2 pathway, inflammation and atherosclerosis: trigger and target? Int J Cardiol. 2018;267:188–192.
  • Pusceddu I, Dieplinger B, Mueller T. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans. Clin Chim Acta. 2019;495:493–500.
  • Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33/ST2 axis in organ fibrosis. Front Immunol. 2018;9:2432.
  • Mueller T, Jaffe AS. Soluble ST2 – analytical considerations. Am J Cardiol. 2015;115(7):8B–21B.
  • Lin YH, Zhang RC, Hou LB, et al. Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes. Diabetes Res Clin Pract. 2016;118:140–145.
  • Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med. 1998;15(7):539–553.
  • Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402–2410.
  • Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854.
  • Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.
  • Vasunta R-L, Kesäniemi YA, Ylitalo A, et al. Nondipping patter and carotid atherosclerosis in a middle-aged population: OPERA study. Am J Hypertens. 2012;25(1):60–66.
  • Rantala AO, Kauma H, Lilja M, et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med. 1999;245(2):163–174.
  • Leinonen T, Kesäniemi YA, Hedberg P, et al. Serum ghrelin and prediction of metabolic parameters in over 20-year follow-up. Peptides. 2016;76:51–56.
  • Pascual-Figal DA, Lax A, Perez-Martinez MT, et al. Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2016;54(1):29–35.
  • Fousteris E, Melidonis A, Panoutsopoulos G, et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol. 2011;10(1):101.
  • Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922.
  • Bai F, Ba F, You Y, et al. Decreased ST2 expression is associated with gastric cancer progression and pathogenesis. Oncol Lett. 2019;17:5761–5767.
  • Larsen KM, Minaya MK, Vaish V, et al. The role of IL-33/ST2 pathway in tumorigenesis. Int J Mol Sci. 2018;19(9):2676.
  • De la Fuente M, MacDonald TT, Hermoso MM. The IL-33/ST2 axis: role in health and disease. Cytokine Growth Factor Rev. 2015;26(6):615–623.
  • Roberts R, Knopman DS. Classification and epidemiology of MCI. Clin Geriatr Med. 2013;29(4):753–772.
  • Xiong Z, Thangavel R, Kempuraj D, et al. Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimers Dis. 2014;40(2):297–308.
  • Moheet A, Mangia S, Seaquist ER. Impact of diabetes on cognitive function and brain structure. Ann N Y Acad Sci. 2015;1353:60–71.
  • Vieira MNN, Lima-Filho RAS, De Felice FG. Connecting Alzheimer's disease to diabetes: underlying mechanisms and potential therapeutic targets. Neuropharmacology. 2018;136(Pt B):160–171.
  • Chen LQ, de Lemos JA, Das SR, et al. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clin Chem. 2013;59(3):536–546.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.